ライフサイエンスコーパス: ECP

1 ECP after 19-d courses (n = 2,262) was lower in older ch

2 ECP and EDN each induced distinct skin lesions at >or=2.

3 ECP and EDN localized to dermal cells within 2 days, whe

4 ECP bound to oligosaccharides of at least arabinotriose

5 ECP in the nasal lavage increased after the NAC-P in the

6 ECP is a pilus of EHEC O157:H7 with a potential role in

7 ECP is now under investigation for use in patients with

8 ECP is thought to control these diseases in part through

9 ECP levels were >200 ng/ml in 61% of persons with colds

10 ECP plays a dual role in early-stage biofilm development

11 ECP primes IL-1beta production and activates IL-1beta ma

12 ECP production was demonstrated in 121 (71.6%) of a tota

13 ECP release was measured by radioimmunoassay.

14 ECP was generally well tolerated.

15 ECP was initiated approximately 2 years after onset of c

16 ECP-1 monomeric units were also shown to assemble into h

17 ECP-treated autologous splenocytes resulted in immune to

18 ECPs facilitate U1 association with RNAs with weak 5' SS

19 tely 52% identity to the egg case protein 1 (ECP-1) fibroin-like family member.

20 tions (M06-2X/aug-cc-pVDZ/Hay-Wadt VDZ (n+1) ECP), highlighting the remarkable effect of acid on the

21 Relative to ECP-1, ECP-2 mRNA levels were determined to be >2-fold higher.

22 g-2, VEGF, TGF-beta1, Cys-LTs, MMP-2, IL-13, ECP, and IL-8 measurement in supernatants.

23 e have named this factor egg case protein 2 (ECP-2).

24 For both RNase A(ECP) and H48A there is a 10-fold decrease in the product

25 of the product analogue, 3'-CMP, to RNase A(ECP) results in only minor chemical shift changes in the

26 The chimera (RNase A(ECP)) experiences only local perturbations in NMR backbo

27 of the true uncomplexed ECP32-cleaved actin (ECP-actin) solved to 1.9 A resolution is reported.

28 Appropriately modified by future advances, ECP may potentially offer a general source of therapeuti

29 ip between FEV1 versus time before and after ECP.

30 aGVHD achieved complete remission (CR) after ECP.

31 ify patients who died within 16 months after ECP initiation.

32 ith mortality (P = 0.007) at 16 months after ECP initiation.

33 line from the rate of decline 6 months after ECP.

34 real photopheresis (ECP) and mortality after ECP in lung allograft recipients with bronchiolitis obli

35 Immunologic effects observed after ECP included normalization of inverted ratios of CD4 to

36 id refractory cGHVD achieved CR and PR after ECP, respectively.

37 to Th2 (IL-4, IL-10) cytokine profile after ECP, and 8 of 10 had a clinical response to ECP.

38 ng the mechanism leading to a response after ECP.

39 centrates and peripheral blood samples after ECP.

40 An ECP mutant showed only a modest reduction in adherence t

41 MATERIALS AND We analyzed ECP and histamine production in response to LPS by ELISA

42 Alignments of ECP-1 and ECP-2 demonstrate highly conserved N termini, with 16 Cy

43 e fiber, our findings suggest that ECP-1 and ECP-2 play important structural roles in the egg case si

44 stinctive protein architectures of ECP-1 and ECP-2, along with their co-localization with TuSp1 in th

45 ng tubuliform spidroin 1 (TuSp1), ECP-1, and ECP-2.

46 and inflammatory features (IL-12, IL-13 and ECP).

47 ntrations were associated with high IL-5 and ECP protein levels.

48 Levels of IL-6 and ECP did not change significantly during the study.

49 While RNase 7 and ECP/RNase 3 are both cationic and share this particular

50 pression patterns, suggests that RNase 7 and ECP/RNase 3 may have been recruited to target different

51 The correlation between MIP-1-alpha and ECP concentrations suggests a role for eosinophil degran

52 CRSsNP and CRSwNP, identifying S aureus and ECP as novel and crucial players in this process.

53 sess the effect of Staphylococcus aureus and ECP on sRAGE processing.

54 xpression of the Histidine decarboxylase and ECP by flow cytometry and fluorescence microscopy in neu

55 higher levels of histidine decarboxylase and ECP than those from healthy volunteers, and they also re

56 ve to spotlight the unique nature of EDN and ECP and the unusual evolutionary constraints to which th

57 use genes identified as orthologs of EDN and ECP form a highly divergent, species-limited cluster.

58 Both of EPP and ECP were high in methoxyl and rich in galacturonic acid.

59 ethylated crystalline pectin in both EPP and ECP.

60 cigranulocytic, whereas as expected FeNO and ECP were higher in eosinophilic and mixed asthma, while

61 was demonstrated with an ecpR-GFP fusion and ECP antibodies.

62 ge of neutrophils as source of histamine and ECP in the progression of the periodontitis disease.

63 Leukotriene and ECP levels were measured using EIAs or ELISAs.

64 Sputum cys-LT and ECP were a mean (95% CI) 1.6-fold (1.1, 2.5) and 6.4-fol

65 he human eosinophil granule proteins MBP and ECP affect human corneal epithelial cell viability and m

66 Cells treated with MBP and ECP induced a dose-dependent gradual increase in morphol

67 At 24 hours, both MBP and ECP induced statistically significant (P < 0.05) decreas

68 cant increase of eosinophils, monocytes, and ECP in induced sputum at V3 compared with V1.

69 aqueous shunt to extraocular reservoir, and ECP.

70 and functional ortholog of primate EDNs and ECPs.

71 Better communication between PCPs and ECPs, further implementation of EMRs, and increasing eye

72 cells, and the binding was blocked with anti-ECP antibodies, confirming that the pili possess adhesin

73 Because ECP induces normal monocytes to enter the DC differentia

74 Patients whose decline in FEV1 before ECP was statistically significant (P < 0.05) were nearly

75 ed expiratory volume in 1 second just before ECP was associated with mortality (P = 0.007) at 16 mont

76 relationship between FEV1 versus time before ECP initiation.

77 vestigated, attempts to make saturated black ECPs have not been reported, probably owing to the compl

78 f P. aeruginosa to silicon was controlled by ECP, in addition to LPS.

79 suggesting that they were also influenced by ECP, especially polysaccharides.

80 Of interest, IL-1beta maturation by ECP was fully intact in murine cells deficient in caspas

81 induction of immunostimulatory mediators by ECP.

82 ence for promotion of IL-1beta production by ECP and offer new insight into the immunostimulatory cap

83 The induction of this tolerant state by ECP was obviated by cotreatment with lipopolysaccharide,

84 tometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 months.

85 the hypothesis that in patients with cGVHD, ECP modulates alloreactivity by affecting activated lymp

86 The majority (88%) of patients commenced ECP at treatment lines 1 to 3, either as a monotherapy o

87 In conclusion, ECP and EDN disrupt skin integrity and cause inflammatio

88 I 69.7%-79.7%); among 159 inpatient courses, ECP was 47.7% (95% CI 39.7%-57.3%).

89 blade and endoscopic cyclophotocoagulation (ECP) surgeries in patients with primary open angle glauc

90 opic and transscleral cyclophotocoagulation (ECP, TCP) are generally reserved for refractory glaucoma

91 number of endoscopic cyclophotocoagulations (ECPs) increased 99% from 5383 to 10 728.

92 ossmatch tests performed using donor-derived ECPs allow for the identification of alloantibodies that

93 duction and potential stability, the p-doped ECPs with low oxidation potentials such as PPy need to b

94 suggests that early BAFF measurement during ECP for cGVHD represents a potentially useful biomarker

95 nety-five patients were randomized to either ECP and standard therapy (n = 48) or standard therapy al

96 vidence demonstrating that the gene encoding ECP is regulated in an analogous fashion and that an int

97 In addition to cys-LTs, LL-37 enhances ECP release from eosinophils via pERK1/2.

98 also derive a structural model for entwined ECP fibers that not only illuminates interbacteria commu

99 FeNO, ECP and IL-8 were all low in the paucigranulocytic, wher

100 tricted patterns of expression for fibroins, ECP-1 was demonstrated to be predominantly produced in t

101 r lysine-aspirin challenge were analyzed for ECP, tryptase, PGE2 , PGD2 , LTD4 , and LTE4 .

102 Spinach was found to be enriched for ECP/LM13 targets compared with lettuce.

103 e of an inflammasome-independent pathway for ECP-dependent IL-1beta maturation.

104 s the best E(0) reproducibility reported for ECP-based SCISEs.

105 These data suggest an important role for ECP in the biology of ETEC, particularly in CF-negative

106 receiving better communication/feedback from ECPs, (3) having ophthalmologists hold clinic days in pr

107 of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these p

108 lasmid present in nonadherent E. coli HB101, ECP rendered this organism highly adherent at levels com

109 Low haemoglobin was associated with higher ECP.

110 eresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chron

111 there has been progress in understanding how ECP works at the cellular level.

112 The crystal structure of human ECP, determined at 2.4 A, is similar to that of RNase A

113 emical characterization of recombinant human ECP (rhECP) prepared in baculovirus, and demonstrate tha

114 s noted accompanied by minimal elevations in ECP and albumin.

115 number of 34+DR- cells and LTC-IC present in ECP CML marrow was similar to that in normal (NL) marrow

116 e developed a novel method for incorporating ECP treatment into well-established and clinically relev

117 90 both caused inhibition of eotaxin-induced ECP release and chemotaxis.

118 Of particular interest, ECP/RNase 3's cationicity is based on an (over)abundance

119 Hence, MBP, ECP, and EPO perturb the corneal epithelium differential

120 Overall mean ECP was 74.5% (95% CI 69.7%-79.7%); among 159 inpatient

121 High BAFF at 1-month ECP associated with a worsening median 6-month skin scor

122 RAST), nasal eosinophilia, or elevated nasal ECP (odds ratios = 17, 21, and 25, respectively).

123 NSAID-UA subjects showed no changes in nasal ECP, whereas subjects with AERD had increased levels of

124 scribed here is N-glycosylated, as is native ECP, and has approximately 100-fold more ribonuclease ac

125 cellular localization and RNase activity of ECP and EDN were critical for lesion formation; differen

126 te specificity and low catalytic activity of ECP.

127 Alignments of ECP-1 and ECP-2 demonstrate highly conserved N termini,

128 , eosinophils released significant amount of ECP when cultured with RSV-infected A549 cells.

129 ight into the biogenesis and architecture of ECP.

130 ith the distinctive protein architectures of ECP-1 and ECP-2, along with their co-localization with T

131 sight into the immunostimulatory capacity of ECP.

132 In particular, early commencement of ECP at treatment lines 1 to 3 yielded a TTNT of 47 month

133 5%-95%; P < or =.002) after a 2-day cycle of ECP and longitudinally over the 12-month course of thera

134 ess, evidence for considerable divergence of ECP is also implicit in the structure.

135 To further elucidate the effects of ECP on activated lymphocyte subpopulations and the inter

136 To examine the efficacy of ECP in the modern era of novel therapies, we conducted a

137 vealed a significant improvement in favor of ECP (P < .001).

138 produced the novel anti-pathogen function of ECP.

139 detection and more timely implementation of ECP (ie, when FEV1 values >1.5 L) should be considered e

140 (baseline) and 6 months after initiation of ECP were used to plot the linear relationship between FE

141 lls in all patients before the initiation of ECP.

142 at either 6 or 16 months after initiation of ECP.

143 s subjects with AERD had increased levels of ECP, with the highest peak at 15 min after challenge (P

144 -chromosome inactivation) in the majority of ECP CML patients, before and after mobilization and irre

145 BAFF level at 1 month of ECP predicted 3- and 6-month skin disease response, with

146 estigated the distribution and production of ECP among a collection of 136 human CF-positive and CF-n

147 pression of ICAM-1 on A549 cells, release of ECP was inhibited significantly by anti-CD18 mAb, but no

148 tein data base using the primary sequence of ECP-1 revealed similarity to fibroins from spiders and s

149 be identified within the primary sequence of ECP-1.

150 oorly represented in the primary sequence of ECP-2, but scattered blocks of polyalanine were present,

151 At the time of ECP, 22 (49%) and 23 (51%) of 45 patients with aGHVD wer

152 We demonstrate that the use of ECP as a prophylaxis prior to conditioning significantly

153 The use of ECP monotherapy resulted in a significantly longer media

154 ults of our study support the utilization of ECP for SS/e-MF, and we recommend that ECP should be con

155 findings fed into an Expert Consensus Panel (ECP) Delphi approach to establish consensus regarding tr

156 irway secretions from RSV-infected patients; ECP concentrations correlated with MIP-1-alpha concentra

157 n yield (29.17%) than eggplant calyx pectin (ECP; 18.36%).

158 6 evaluable patients in early chronic phase (ECP), a major cytogenetic response with interferon-based

159 e time of mobilization (early chronic phase [ECP] > late CP > accelerated phase).

160 Extracorporeal photochemotherapy (ECP) has been associated with clinical improvement in se

161 Extracorporeal photochemotherapy (ECP) has been shown to be an effective therapy for patie

162 Extracorporeal photochemotherapy (ECP) is widely used to treat cutaneous T-cell lymphoma,

163 al response to extracorporeal photopheresis (ECP) and mortality after ECP in lung allograft recipient

164 nd efficacy of extracorporeal photopheresis (ECP) for 12 to 24 weeks together with standard therapy w

165 Extracorporeal photopheresis (ECP) has demonstrated therapeutic benefit in patients wi

166 Extracorporeal photopheresis (ECP) is a widely used clinical cell-based therapy exhibi

167 Extracorporeal photopheresis (ECP) is an important therapeutic option in steroid-refra

168 Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acu

169 g) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its ther

170 Extracorporeal photopheresis (ECP), a technique that exposes isolated white blood cell

171 Extracorporeal photopheresis (ECP), an immunomodulating procedure that treats pheresed

172 ) treated with extracorporeal photopheresis (ECP).

173 be induced by extracorporeal photopheresis (ECP).

174 The Escherichia coli common pilus (ECP) is produced by commensal and pathogenic E. coli str

175 The Escherichia coli common pilus (ECP) represents a remarkable family of extracellular fib

176 the recently described E. coli common pilus (ECP) to the overall adherence properties of EPEC.

177 factor, herein called E. coli common pilus (ECP), composed of a 21-kDa pilin subunit whose amino aci

178 geted for adherence by E. coli common pilus (ECP; or meningitis-associated and temperature-regulated

179 electrochemically active conducting polymer (ECP) coating the working electrode of an electrochemical

180 accharides (LPS) and extracellular polymers (ECP) on the adhesion of Pseudomonas aeruginosa PAO1 (exp

181 Electrically conducting polymers (ECPs) are one of the most popular types of materials to

182 most recently green electrochromic polymers (ECPs) required for additive primary colour space were in

183 d absolute counts of Treg cells changed post-ECP, and examined correlation with response.

184 among cGvHD patients, and the increase post-ECP was not significant until 6 months.

185 higher median Treg cell counts 3 months post-ECP than nonresponders, as did steroid responders at 56

186 or Treg cells at baseline to 12 months post-ECP were compared with changes in skin disease scores or

187 hanges in CD4+ % at 6, 9, and 12 months post-ECP.

188 sponders at 56 weeks who were 12 months post-ECP.

189 g donor-derived endothelial cell precursors (ECPs) and kidney allograft rejection and function.

190 en randomly showed that 58% of them produced ECP independently of the presence or absence of CFs, a p

191 The use of prophylactic ECP may provide an alternative and safe method for immun

192 We injected eosinophil cationic protein (ECP or RNase 3), eosinophil-derived neurotoxin (EDN or R

193 ranule proteins eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO) (P < .05), while IF

194 es and (ii) the eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) genes.

195 The genes for eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) in primates

196 Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN), the eosino

197 toxin (EDN) and eosinophil cationic protein (ECP) are both small, cationic ribonuclease toxins that a

198 immunoassay, eosinophilic cationic protein (ECP) by fluoroimmunoassay, prostanoids (PGE(2), PGD(2),

199 hil numbers and eosinophil cationic protein (ECP) in both nasal washes and serum, along with total Ig

200 ctoferrin and eosinophilic cationic protein (ECP) in nasal secretions.

201 ncentrations of eosinophil cationic protein (ECP) in the asthmatic group (p = 0.08).

202 Eosinophil cationic protein (ECP) is located in the matrix of the eosinophil's large

203 Eosinophil cationic protein (ECP) is one of two RNase A-superfamily ribonucleases fou

204 eotaxin-induced eosinophil cationic protein (ECP) release and chemotaxis.

205 ociation with eosinophilic cationic protein (ECP) was detected by fluorescence staining techniques an

206 -8, IL-13 and eosinophilic cationic protein (ECP) were also measured in sputum supernatant.

207 RAGE, IL-5, and eosinophil cationic protein (ECP) were quantitatively assessed in inflamed tissue of

208 ncentrations of eosinophil cationic protein (ECP), a cytotoxic protein contained in the granules of e

209 and 8 (IL-8), eosinophilic cationic protein (ECP), and myeloperoxidase (MPO) as markers of response t

210 ifferentials, eosinophilic cationic protein (ECP), and tryptase were evaluated.

211 eukotrienes and eosinophil cationic protein (ECP), are well-known mediators of inflammation and tissu

212 protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derive

213 as the human eosinophilic cationic protein (ECP), from intracellular granules is central to the role

214 se A homologue, eosinophil cationic protein (ECP), replaced the 12-residue loop 1 in RNase A.

215 h SCORAD score, eosinophil cationic protein (ECP), total IgE, IL-4, IL-13 and IL-31 in children with

216 toxin (EDN) and eosinophil cationic protein (ECP), which have incorporated nonsilent mutations at ver

217 NACs to measure eosinophil cationic protein (ECP).

218 toxin (EDN) and eosinophil cationic protein (ECP).

219 phil counts and eosinophil cationic protein (ECP)] induced by bronchial instillation of house dust mi

220 N, RNase 2) and eosinophil cationic protein (ECP, RNase 3), from >50 human individuals.

221 DN/RNase 2) and eosinophil cationic protein (ECP/RNase 3), are among the most rapidly evolving coding

222 cationic RNase, eosinophil cationic protein (ECP/RNase 3, pI 11.4).

223 ognition of the BS by the E complex protein (ECP) branchpoint bridging protein (BBP).

224 degranulation (eosinophil cationic protein [ECP] in BAL fluid) and lung injury, which largely resolv

225 poor communication from eye care providers (ECPs), (2) patients' lack of finances/insurance coverage

226 Purified ECP bound in a dose-dependent manner to epithelial cells

227 factor (BAFF) in 46 cGVHD patients receiving ECP before and during treatment course.

228 lines in the United Kingdom that recommended ECP for patients with advanced CTCL, particularly after

229 nd thus of the two eosinophil ribonucleases, ECP and eosinophil-derived neurotoxin (EDN)] remains con

230 BDNF correlated with disease activity, serum ECP, and total IgE serum levels in AD.

231 s with the hypereosinophilic syndrome showed ECP and EDN deposition comparable to that in guinea pig

232 No significant change in sputum ECP and tryptase was observed between rPAF-AH and placeb

233 The CR rate in patients who started ECP being nonresponsive and in PR after steroid was 86%

234 survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; P = 0.07

235 tivity), EPP showed higher value rather than ECP.

236 We found that ECP and BFP structures can be simultaneously observed in

237 Our data indicate that ECP is an accessory factor that, in association with BFP

238 We infer that ECP is effective even in patients with extensive cutaneo

239 on of ECP for SS/e-MF, and we recommend that ECP should be considered as early as possible in the tre

240 This study reveals that ECP induces a high percentage of processed monocytes to

241 In this article, we show that ECP promotes marked release of the prototypic immunostim

242 iption quantitative PCR analysis showed that ECP-2 is predominantly expressed in the tubuliform gland

243 Our results suggest that ECP alters alloreactivity by affecting allo-targeted eff

244 These results suggest that ECP may have a steroid-sparing effect in the treatment o

245 The results suggest that ECP modulates both NK cells and APC populations in patie

246 Our data suggest that ECP production is a common feature of E. coli colonizing

247 in the core fiber, our findings suggest that ECP-1 and ECP-2 play important structural roles in the e

248 genic mutant strains tested, suggesting that ECP plays a synergistic role in adherence.

249 The ECP agreed that training in nontechnical skill assessmen

250 The ECP reached consensus regarding who should be targeted t

251 The ECP(C(10)-C(30)) concentrations ranged from 1.5 to 67 mu

252 ong to the ribonuclease gene family, and the ECP gene, whose product has an anti-pathogen function no

253 the reporter gene activity supported by the ECP promoter/exon 1/intron construct.

254 rovement in TSS at week 12 was 14.5% for the ECP arm and 8.5% for the control arm (P = .48).

255 than that of synonymous substitution for the ECP gene.

256 ecrease from baseline in TSS was 8.3% in the ECP arm at week 12 and 0% in the control arm (P = .04).

257 The NFAT-1 consensus site in the ECP gene differs from that found in the EDN gene by a si

258 doping ion by which the oxidized form of the ECP becomes hydrophobic.

259 rated in the early stage of evolution of the ECP gene.

260 sidues are distributed on the surface of the ECP molecule that may have implications for an understan

261 This article reviews the evolution of the ECP technique--for example, the most recent generation o

262 st to the much more open conformation of the ECP-actin's nucleotide binding cleft in solution, the cr

263 Principal component analysis of the ECP-induced monocyte transcriptome reveals that activati

264 The forward primer is attached to the ECP.

265 ch mapped to two distinct regions within the ECP-1.

266 The first criterion requires that the ECPs are in their oxidized state, but the high charge de

267 e distinctive molecular signature, common to ECP-processed monocytes from normal subjects, and those

268 ned to erlotinib alone (arm A; n = 81) or to ECP (arm B; n = 100).

269 Relative to ECP-1, ECP-2 mRNA levels were determined to be >2-fold h

270 times (P = 0.008) more likely to respond to ECP.

271 e 12 times more likely to have a response to ECP (P = 0.0001).

272 predictor of mortality, and the response to ECP is influenced by both the extent (>40 mL/mo) and sta

273 ters that may be associated with response to ECP or mortality at either 6 or 16 months after initiati

274 Response to ECP was assigned when a positive integer was derived aft

275 We reported that clinical response to ECP was associated not only with normalization of skewed

276 parameters predicted a favorable response to ECP, so patient selection must continue to be made on cl

277 ECP, and 8 of 10 had a clinical response to ECP.

278 ited in 6 Italian centers, were submitted to ECP for second-line treatment.

279 on of both AECAs and HLA antibodies bound to ECPs was performed using flow cytometry.

280 Processable black-to-transmissive ECPs promise to affect the development of both reflectiv

281 lation, were equally effective in triggering ECP release if they were cultured with eosinophils in th

282 lyzed for immune cell populations, tryptase, ECP, and sIgE.

283 e, containing tubuliform spidroin 1 (TuSp1), ECP-1, and ECP-2.

284 These lesions were ulcerated (ECP) or crusted (EDN) with marked cellular infiltration.

285 lution, the crystal structure of uncomplexed ECP-actin contains actin in a typical closed conformatio

286 s from patients with chronic GVHD undergoing ECP therapy.

287 rse VBLL as a percentage of pre-course VBLL (ECP).

288 of additional subtypes of glaucoma, whereas ECP and TCP are generally reserved for refractory glauco

289 is rarely found in other organisms, whereas ECP is widespread in E. coli and other environmental ent

290 The efficiency with which ECP stimulates new functional DCs supports the possibili

291 high in HG (homogalacturonan) (58.6%), while ECP was high in RG-I (rhamnogalacturonan-I) (44.9%).

292 the release of sRAGE from the tissue, while ECP was shown to be implicated in the breakdown of free

293 ing of mitochondrial DNA in association with ECP in a concentration- and time-dependent manner.

294 ents were observed for EPP in comparing with ECP.

295 the relative associations of covariates with ECP.

296 In patients with ECP CML, mobilized PB collections yielded significantly

297 with blood involvement who were treated with ECP at our institute.

298 rate that the transfer of cells treated with ECP reverses established GVHD by increasing donor regula

299 s who had refractory cGVHD were treated with ECP, and the clinical response to and immunologic effect

300 oxicity was greater in patients treated with ECP.